Business, energy, technology, markets and global industry news from Business News Today

aflibercept

PharmaDeviceNews aflibercept
Representative image: Retina specialists review OCT scans as EyePoint’s $EYPT DURAVYU completes enrollment in two Phase 3 diabetic macular edema trials testing six-month dosing against aflibercept.
Pharma & Biotech

DURAVYU pivotal trials move closer to testing a longer-lasting diabetic eye treatment

DURAVYU completes enrollment in two Phase 3 DME trials testing six-month dosing against aflibercept, with results expected in late 2027.

Read More
Biocon’s Yesafili aflibercept biosimilar is gaining new clinical support for retinal treatment and diabetic macular edema ahead of its planned U.S. launch. Representative image.
Pharma & Biotech

Biocon’s Yesafili has FDA approval, but these new switching results may decide whether eye specialists embrace it

Biocon’s new Yesafili studies add switching and subgroup evidence ahead of a planned U.S. launch in the competitive aflibercept market.

Read More
Representative image showing retinal eye care and injectable ophthalmology treatment as Samsung Bioepis expands Europe’s aflibercept biosimilar market with the launch of OPUVIZ for major retinal diseases.
Pharma & Biotech

Can Samsung Bioepis reshape Europe’s retinal disease biosimilar market with OPUVIZ?

Find out how Samsung Bioepis’ OPUVIZ launch could reshape Europe’s aflibercept biosimilar market and ophthalmology access.

Read More
Representative image: Bayer’s planned Perfuse Therapeutics acquisition highlights the intensifying race to develop next-generation ophthalmology treatments beyond Eylea, with PER-001 adding a potential new pathway for glaucoma and diabetic retinopathy innovation.
Pharma & Biotech

Inside Bayer’s $2.45bn push to defend its ophthalmology franchise

Eylea is under pressure. Bayer’s $2.45bn Perfuse bet tests whether PER-001 can carry its next ophthalmology growth story.

Read More
Representative image of retinal injection research and ophthalmology diagnostics used to illustrate Innovent Biologics’ Phase 3 efdamrofusp alfa breakthrough in neovascular age-related macular degeneration treatment.
Pharma & Biotech

Extended-interval nAMD therapy gets a new contender as Innovent Biologics posts Phase 3 STAR data

Innovent Biologics’ efdamrofusp alfa cleared a key Phase 3 nAMD hurdle in China. Read what the STAR data could change for retinal treatment.

Read More
Pharma & Biotech

GoldenTree backs Alvotech with $100m financing to accelerate pipeline execution

Alvotech secures $100M loan to fund 2026 biosimilar launches and R&D. Find out how this financing reshapes its global strategy.

Read More